United States· US:49884-425_6c3a1f0c-dd67-4849-a8b5-a88f85ac5f43
ALISKIREN
A aliskiren product containing aliskiren, registered in United States by Endo USA, Inc.. The same ATC class is registered in 13 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Aliskiren is registered in 13 of 19 countries.
Countries holding a registration under ATC C09XA02 (aliskiren), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 9 of them publish a price we can compare per daily dose
Aliskiren · ATC C09XA02
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of aliskiren costs, country by country.
Normalised to the WHO defined daily dose (0.15 g), the median price runs from $0.95 in Italy to $3.43 in United States — a ×3.6 gap.
- United States: $3.43 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Aliskiren · price per daily dose (0.15 g)
USD · FX 28 Sept 2026
- US United States$3.43 (acquisition cost)
- IT Italy$0.95
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- ALISKIREN
- Manufacturer
- Endo USA, Inc.
- Country
- United States (US)
- ATC code
- C09XA02
- ATC class
- Aliskiren
- Defined daily dose
- 0.15 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 12, 2026
Packs & prices · 1
- ndc11498844251130 TABLET, FILM COATED in 1 BOTTLE (49884-425-11)
Regulatory notes
Interactions
227 interactions on record for aliskiren.
Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Aliskiren · interactions on record
227 records
- 1 severe
- 147 moderate
- 26 info
Most severe, free to view
- CiclosporinL04AD01severe
- ClotrimazoleA01AB18moderate
- AprepitantA04AD12moderate
- RolapitantA04AD14moderate
53 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Aliskiren in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainRASILEZ 300 mg COMPRIMIDOS RECUBIERTOS CON PELICULANovartis Europharm Limited
- SwitzerlandRasilez 300 mg, FilmtablettenFuture Health Pharma GmbH
- IcelandRasilezNoden Pharma DAC
- NetherlandsRasilez 300 mg, filmomhulde tabletNoden Pharma DAC
- PolandRasilezNoden Pharma DAC
- SwedenRasilez 300 mg Filmdragerad tablettLXO Ireland DAC
- United KingdomRasilez 150mg tabletsWaymade Healthcare Plc
- NorwayRasilezNoden Pharma
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Rasilez
- Liechtenstein · Rasilez
- Norway · Rasilez
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9d707098-ec6a-45ce-b867-0a6974672869 GET /v1/drugs/9d707098-ec6a-45ce-b867-0a6974672869?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unii": {
"unii": "C8A0P8G029",
"rxcui": "732498",
"inchikey": "KLRSDBSKUSSCGU-KRQUFFFQSA-N",
"display_name": "ALISKIREN HEMIFUMARATE",
"substance_type": "chemical",
"ingredient_type": "INGREDIENT SUBSTANCE"
},
"route": "ORAL",
"livertox": {
"summary": null,
"livertox_id": null,
"hepatotoxicity_score": 3
},
"spl_meta": {
"f3fd2503-25ef-4660-a29a-f62c491e28fb": {
"match": "brand_token",
"title": "ALISKIREN TABLET, FILM COATED [ENDO USA, INC.]",
"spl_version": "29",
"published_date": "2024-09-26"
}
},
"productid": "49884-425_6c3a1f0c-dd67-4849-a8b5-a88f85ac5f43",
"productndc": "49884-425",
"dosage_form": "TABLET, FILM COATED",
"orange_book": {
"appl_no": "206665",
"products": [
{
"rs": false,
"rld": false,
"te_code": "AB",
"strength": "EQ 150MG BASE",
"product_no": "001",
"approval_date": "Mar 22, 2019"
},
{
"rs": false,
"rld": false,
"te_code": "AB",
"strength": "EQ 300MG BASE",
"product_no": "002",
"approval_date": "Mar 22, 2019"
}
],
"appl_type": "A"
},
"dea_schedule": null,
"product_type": "HUMAN PRESCRIPTION DRUG",
"substance_name": "ALISKIREN HEMIFUMARATE",
"proprietary_name": "ALISKIREN",
"active_ingred_unit": "mg/1",
"application_number": "ANDA206665",
"marketing_category": "ANDA",
"nonproprietary_name": "ALISKIREN",
"start_marketing_date": "20190325",
"active_numerator_strength": "300"
}See everything about aliskiren.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.